Detalhe da pesquisa
1.
A Novel Machine Learning Algorithm Predicts Dementia With Lewy Bodies Versus Parkinson's Disease Dementia Based on Clinical and Neuropsychological Scores.
J Geriatr Psychiatry Neurol
; 35(3): 317-320, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33550890
2.
The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes.
Br J Haematol
; 192(6): 978-987, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32862447
3.
Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes.
Hematol Oncol
; 38(4): 541-553, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32495951
4.
Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group.
Am J Hematol
; 95(5): 465-471, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32048329
5.
The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group.
Hematol Oncol
; 36(4): 693-700, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30129144
6.
Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
Ann Hematol
; 97(9): 1671-1682, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29756171
7.
Correction to: Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
Ann Hematol
; 97(9): 1747, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29943159
8.
The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group.
Am J Hematol
; 93(7): 895-901, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29659040
9.
The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms.
Am J Hematol
; 98(5): E119-E122, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36808739
10.
"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.
Ann Hematol
; 93(1): 129-39, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23892921
11.
The incidence of myelodysplastic syndromes in Western Greece is increasing.
Ann Hematol
; 92(7): 877-87, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23572136
12.
Newonset nonmotor symptoms in patients with Parkinson's disease and postCOVID19 syndrome: A prospective crosssectional study.
Med Int (Lond)
; 3(3): 23, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37214229
13.
The Assessment of the Socioemotional Disorder in Neurodegenerative Diseases with the Revised Self-Monitoring Scale (RSMS).
J Clin Med
; 11(24)2022 Dec 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36555991
14.
Clock-Drawing Tasks as Predictive Measurements for Disease Classification Among Patients With Parkinson's Disease and Essential Tremor.
Cureus
; 13(2): e13239, 2021 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33728188
15.
Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" Study.
J Clin Med
; 10(7)2021 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33916376
16.
Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes.
Ther Adv Hematol
; 11: 2040620720966121, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33343854
17.
Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine Registry.
Clin Lymphoma Myeloma Leuk
; 20(2): 114-121, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31884152
18.
The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5-azacytidine: Results from the Hellenic 5-azacytidine registry.
Cancer Med
; 8(5): 2056-2063, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30897290
19.
Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in patients' outcome?
Leukemia
; 37(12): 2517-2519, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37816955
20.
Myelodysplastic neoplasm with isolated thrombocytopenia and immune thrombocytopenic purpura in adults: insights from a comparison of two national registries.
Leukemia
; 37(3): 708-711, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36646886